Abstract
Overview
Introduction
The neuropathic pain market is forecast to almost triple to over $6.3 billion
by the end of the forecast period in 2017. The growth in the market is spurred
on by the uptake of Pfizer' s Lyrica (pregabalin), forecast to reach almost $3
billion in sales by 2017. Vimpat is the most promising pipeline drug, forecast
to take some $480m by 2017.
Scope
- Analysis of patient potential, unmet needs and clinical trial design in
the neuropathic pain market.
- Overview of key marketed brands, late- and early-stage pipeline drugs.
- Country-specific sales volume and value forecasts to 2017 of marketed
brands, generics, and key late-stage pipeline drugs.
- Identification of future market events that are expected to affect
neuropathic pain revenues.
Highlights
UCB' s Vimpat (lacosamide) demonstrates the most potential in the pipeline and
is well suited to compete in this market. Datamonitor has forecast Vimpat to
generate over $480m, over a third of the total pipeline sales by 2017.
Neuropathic pain offers diverse market opportunities, with niche underserved
neuropathic pain indications (e.g. HIV associated neuropathic pain) offering a
good market entry point.
Following the recent negative FDA advice on Cephalon' s Fentora, Datamonitor
has forecast that the drug will not launch for neuropathic pain. This is a
blow to the development of a niche breakthrough neuropathic pain market.
Reasons to Purchase
- Benchmark key late-stage pipeline neuropathic pain drugs against current
market leading brands.
- Assess country-specific (US, Japan, France, Germany, Italy, Spain and the
UK) sales forecasts of key late-stage pipeline drugs and marketed brands.
- Understand unmet needs and opportunities in the neuropathic pain market
based on key opinion leader comments.
| 
View Cart
